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Modulation of renal EGF in dichromate-induced acute renal
failure treated with thyroid hormone
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Department of Nephrology, Walter Reed Army Insritute of Research, Washington, D.C., USA
Modulation of renal EGF in dichromate-induced acute renal failure
treated with thyroid hormone. Administration of either thyroid hormone
or epidermal growth factor (EGF) ameliorates injury in a variety of
experimental acute renal failure (ARF) models. Since thyroid hormone
augments EGF release and EGF receptor expression, a hypothesis
suggesting that the mechanism of thyroid action is via EGF appears
attractive. The present study is an attempt to evaluate the role of EGF
in thyroid mediated protection from ARF induced in rats by dichro-
mate. Renal parenchymal levels of acid extractable endogenous EGF
were measured by RIA in dichromate exposed, otherwise untreated
animals and in those receiving dichromate followed by thyroid. In the
untreated case serum creatinine peaked at 2.5 mg % on the third day
following dichromate exposure. Endogenous levels of EGF closely
paralleled serum creatinine with a six-fold increase observed at peak
injury. The source of EGF increase appeared to be a membrane bound
precursor as soluble levels of EGF rose in injured kidneys at the
expense of Triton-X-lOO extractable, immunoreactive material that
upon treatment with trypsin yielded additional EGF. T3 administered
one hour following dichromate resulted in significant functional protec-
tion (peak injury serum creatinines 2.63 0.76 control vs. 0.98 0.14
with T3) as well as an approximate doubling in renal EGF levels at 24,
48 and 72 hours (4.7 0.3 vs. 9.7 0.8 at 24 hr, 33.5 6.5 vs. 63,2
20.0 at 48 hr, and 23.1 10.0 vs. 44.1 8.7 nglg wet weight at 72 hr).
There was no beneficial effect of exogenous EGF on renal function
either when given in conjunction with T3 or when used alone. These
data suggest the existence of a self protection mechanism where injured
renal tissues release EUF to stimulate repair and recovery.
Epidermal growth factor (EGF) is a potent cellular mitogen
recently shown to accelerate recovery from both ischemic and
toxic acute renal failure (ARF) [1—3]. Administration of EGF
following renal injury attenuates the maximal degree of func-
tional impairment, increases the rate of thymidine incorporation
into renal parenchymal cells and improves histologic appear-
ance. It has therefore been postulated that exogenous EGF acts
simply through its mitogenic effect to repair or replace injured
renal epithelia. Since the kidney is a major source of EGF
synthesis the viability of this hypothesis relies, to some extent,
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on measurement of renal EGF in the control setting in ARF and
in ARF treated with exogenous EGF. It is known that messen-
ger RNA for the membrane bound EGF precursor markedly
decreases in some models of ARF as does urinary excretion of
EGF [4, 5]. While these data suggest that endogenous kidney
EGF might be decreased during ARF consistent with the
salutary effect of exogenously administered compound, recent
direct measurements of endogenous EGF suggest that tissue
levels in ischemic ARF actually increase significantly following
injury [6].
Thyroid hormone has also been shown to be protective when
administered following renal injury in a variety of experimental
models [7—11]. The mechanism of action of thyroid, while
unknown, is thought to be related to enhanced epithelial repair
or recovery, perhaps through the enhanced flow of metabolic
energy [11] or through the induction of enzymes necessary for
cellular integrity or repair [7, 8, 10, 11]. It has been suggested
that thyroid hormone and EGF act through common or syner-
gistic mechanisms [12]. Thyroid has been shown to increase
both tissue and urinary levels of EGF in normal animals [13],
and to increase the number of EGF receptors in tubular
epithelial cells in tissue culture [12]. In the present studies a
nephrotoxin-induced rat ARF model (dichromate) was em-
ployed to analyze the possible modulation of endogenous EGF
by the injury itself and treatment with thyroid hormone and/or
exogenous EGF. In addition, an assessment of kidney function
was performed by measuring serum creatinine to compare the
effects of thyroid and exogenous EGF in the setting of dichro-
mate induced injury and determine whether synergism between
the two agents could be demonstrated.
Methods
All studies were performed in male Sprague-Dawley rats
weighing 225 to 350 g. Mean animal weights and baseline serum
creatinines were similar in all groups compared. In experimen-
tal animals, toxic acute renal failure was induced by the
subcutaneous injection of a freshly prepared solution of potas-
sium dichromate (15 mg/mI) at a dose of 15 mg/kg body weight.
These animals received tri-iodo-thyronine (T3), human recom-
binant epidermal growth factor (hr-EGF) or saline at varying
intervals following dichromate. Separate controls of dichro-
mate-induced renal failure were performed for comparison with
each treatment. T3 was administered as a single intraperitoneal
injection at a dosage of 10 g/100 g body weight either 1 or 24
hours following dichromate. The hr-EGF was given as a single
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Table 1. Effect of dichromate on serum creatinine and renal EGF
0 hr 24 hr 48 hr 72 hr 96 hr 144 hr
Creatinine 0.57 0.04 0.56 0.05 l.48a 0.15 1.87° 0.31 1.19k 0.22 0,55 0.06
mg/% (30) (30) (27) (23) (17) (10)
EGF-cortex 12.2 0.9 23.0° 7.6 535a 14 74.2a 26 56.6a 16 18.8 1.4
ng/g wet wt (11) (4) (5) (6) (5) (2)
EGF-medulla 16.7 1.8 31.5a 6.2 iiia 11 97.5° 12 isoa 25 19.2 0.9
ng/g wet wt (14) (7) (7) (6) (8) (2)
Serum creatinine and EGF content of cortex and medulla were measured at varying intervals following dichromate. Data are mean SEM. N
at each time point is indicated in parentheses.
a Significantly different from the same measure at time 0, P < 0.05
subcutaneous injection (7 j.g/l00 g body wt) four hours follow-
ing dichromate.
Serum creatinine was used as an index of renal function.
Blood was obtained by serial tail vein bleedings. Serum creat-
mine was measured in duplicate with a Beckmann Creatinine
Analyzer (Beckman Instruments, Fullerton, California, USA)
and the mean value was used for all statistical analyses.
To measure acid extractable renal EGF levels, animals were
first anesthetized with phenobarbital, 30 mg/kg i.p.. The pen-
toneal cavity was opened and the renal arteries were isolated.
Kidneys were flushed with normal saline (4°C), removed, and
placed on ice. Cortex and medulla were dissected and homog-
enized in 0.5 M acetic acid (10:1 acid:tissue by weight) using a
Brinkman Polytron at setting six for 45 seconds. Homogenates
were centrifuged at 34,000 g for 30 minutes at 4°C, and the
supernatants were collected, frozen at —70°C, lyophilized and
stored for EGF determination performed in duplicate by homol-
ogous radioimmunoassay as previously described [14]. These
samples represent acid soluble material from cytosol. To exam-
ine the source of the observed rise in acid extractable EGF the
immunoreactive activity in soluble versus membrane bound
form was analyzed.
Homogenates were prepared as above but in 10 volumes 20
mM HEPES, 10 m Na, 2 mM MgCl2, pH 7.5. Soluble ir-EGF
extracted following homogenization with either acid or HEPES
buffer gave similar results on RIA (data not shown). These
suspensions were centrifuged at 100,000 g for 30 minutes at 4°C.
Supernatants were retained for assay and the pellets were
washed with the original volume of buffer and recentrifuged as
above. The washed pellet was homogenized in 7 volumes of 20
mM HEPES, 150 m NaCI, 1% Triton X-100, pH 7.5 and
respun at 100,000 g for 30 minutes. The pellet was discarded and
the supernatant was kept for further analysis. This sample
represents detergent extractable material from a crude particu-
late fraction comprising cellular membranes and organelles. For
enzymatic digestion, one ml of this supernatant was incubated
with 100 p.g trypsin added in a volume of 100 a1 in 100 ma
sodium phosphate, pH 7.5, for one hour at 37°C. The reaction
was terminated by the addition of 500 g soybean trypsin
inhibitor in 100 p1 phosphate buffer. EGF assay was as refer-
enced above.
T3, trypsin, and soybean trypsin inhibitor were obtained from
Sigma Chemical Co., (St. Louis, Missouri, USA). The hr-EGF
was obtained from Upstate Biotechnical, Inc. All chemical
reagents were of analytical grade and obtained from Sigma.
Statistics were performed using Fisher's protected t-test
following analysis of variance for comparisons of multiple
groups. Significance was taken at the level P < 0.05.
Results
The effect of dichromate on serum creatinine and renal tissue
EGF levels is shown in Table 1. There was a progressive rise in
creatinine which peaks at day 3 in the range of 2 mg %,which
then returned to normal by day 6. The same pattern was seen
with renal acid extractable EGF. The peak in medulla (150 25
ng/g wet tissue) was later (day 4) than that in the cortex (74.2
26 ng/g wet tissue) (day 3). In both locations tissue EGF levels
returned to normal by day 6 when functional recovery was
complete. Clearly, tissue EGF rose along with injury and
returned to normal with recovery.
Large molecular weight precursors of EGF have been de-
scribed as membrane associated proteins in mouse [15] and
recently in rat [6]. Proteolysis of these precursors with either
pepsin [15] or trypsin [6] has been reported to release biologi-
cally active EGF. To examine the possibility that the increased
renal EGF seen during dichromate-induced acute renal failure
might derive from a membrane bound precursor, membrane
pellets and soluble cellular material were analyzed for EGF
content. Whole kidney homogenates were examined 48 hours
following dichromate. As shown in Figure 1, soluble fractions
extracted with a HEPES buffer showed an increase in EGF with
renal failure similar to that seen with acid extraction (59.6
12.3 ng/g wet wt at 48 hr compared with 9.6 0.8 ng!g wet wt
in control). When membrane pellets were extracted with Triton
X-100 a different pattern emerged. Triton extracts from control
kidneys (16.5 0.8 nglg wet wt) had higher EGF levels than
those from renal failure kidneys (6.0 0.6 ng/g wet wt). When
these extracts were treated with trypsin, there was a much
greater liberation of immunoreactive EGF from control mem-
branes (227 17.7 nglg wet wt) than from membranes of renal
failure animals (72.2 12.2 ng/g wet wt).
The effect of thyroid hormone (T3, 10 pgI100 g) on the course
of dichromate induced acute renal failure is shown in Figure 2.
When given one hour following dichromate, T3 markedly re-
duced the rise in serum creatinine, and resulted in almost
complete recovery by day 4. When given 24 hours following
dichromate, T3 blunted the severity of renal failure, but this was
significant only at 48 hours. In contrast to T3, recombinant
EGF, given at a dosage and time (7 g/100 g weight 4 hr
post-injury) previously described as efficacious in ischemic and
heavy metal-induced acute renal failure [1, 2], had no significant
effect on serum creatinine following dichromate (Table 2).
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Fig. 1. Relation of soluble to membrane bound ir-EGF. Kidneys from
control (hatched bars) or dichromate treated (open bars) animals were
examined 48 hours after dichromate injection. Significantly greater
levels of soluble ir-EGF are found in Hepes extracts from renal failure
kidneys than from control. When membrane fractions are extracted
with triton (middle panel) there is more ir-EGF released from control
kidneys; when this material is exposed to proteolytic digestion with
trypsin there is a fivefold greater release of ir-EGF from control kidneys
than from renal failure kidneys. In all cases, control and dichromate
values are significantly different, P < 0.05. N = 6 to 8 per group. Data
are mean SEM.
To examine whether T3 and exogenous EGF have synergistic
effects, 13 was given one hour following dichromate, and EGF
was given four hours following dichromate. As shown in Table
3, the results of these experiments at all time periods from days
0 to 6 were not statistically different from those obtained with
T3 alone.
We next examined the effect of both 13 and exogenous EGF
on tissue EGF content in ARF. Under control conditions T3 had
a significant stimulatory effect on renal EGF content, increasing
it from 4.7 0.3 to 6.6 0.5 nglg wet wt (N = 6, P < 0.01). The
effects of T3 or EGF on renal EGF content at 24, 48 and 72
hours following dichromate are shown in Table 4. T3 signifi-
cantly increased renal EGF levels at all time periods, while
exogenous EGF had no effect. Although control levels of
ir-EGF in these animals were somewhat lower than those
described above, a similar six- to eightfold increase in ir-EGF
was seen at 48 hours following injury. (The human recombinant
EGF could not be measured in the RIA performed for these
studies since the anti-EGF antibody utilized does not recognize
human EGF.)
Discussion
Both thyroid hormone and EUF promote recovery and blunt
the course of experimental acute renal failure. Thyroid hor-
mone has been documented by ourselves [161 and others [13] to
increase the levels of soluble EGF in rodent kidneys sevenfold
over a three day period. In addition, thyroid hormone has been
documented to increase renal GGF receptor expression [12]. A
unifying hypothesis would propose that both agents act through
a common mechanism. In the simplest scenario renal levels of
EGF would be below the Kd of available receptors both in the
control setting and following injury. The infusion of exogenous
Time, hours
Fig. 2. Effect of T3 on dichromate induced ARF. Control animals (open
circles) had a progressive rise in serum creatinine which peaked at day
3. Animals receiving T3 1 hour following dichromate (closed circles) had
almost complete attenuation of ARF at days 2, 3 and 4. Animals
receiving T3 24 hours (triangles) had significantly less functional impair-
ment at 48 hours. N = 20 to 30 per group. Data are mean SEM.
* different from controls P < 0.05.
EGF would directly raise kidney parenchymal EGF concentra-
tions whereas the infusion of thyroid hormone would augment
these levels indirectly, through the stimulation of EGF synthe-
sis or through activation of a latent precursor. In either case the
result would be EGF receptor activation and the mitogenesis
necessary for functional recovery. Thyroid effects on EGF
receptor number would be complementary and might lead to
synergism when both agents are provided together.
Available evidence provided support for an important feature
of this schema. Decreased levels of renal preproEGF messen-
ger RNA and decreased urinary excretion of EGF in alternative
models of ARF [4, 5] were compatible with diminished tissue
concentrations of EGF with injury, levels perhaps below those
necessary for receptor occupancy and maximal activation. In
results reported here, however, renal soluble immunoreactive
EGF content rose markedly as kidney function declined in the
absence of treatment and returned toward normal as function
improved. Interestingly, the source of the rise in endogenous
EGF appears to be via release from a membrane bound precur-
sor. Such a large molecular weight multimer has been described
in the mouse [15] and recently in the rat [6]. In the experiments
reported here Triton X-100 extraction of crude membranes
revealed an apparent decrease in membrane bound immunore-
active EGF following ARF. More importantly, proteolysis of
the Triton extractable material with trypsin released signifi-
cantly more EGF activity from control kidneys than from renal
failure kidneys. These data suggest that the mechanism result-
ing in the rise in endogenous soluble immunoreactive EGF may
involve the activation of specific proteases which occurs as a
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Table 2. Effect of exogenous EGF on dichromate-induced acute renal failure
0 hr 24 hr 48 hr 72 hr 96 hr 144 hr
Dichromate 0.42 0.05 0.80 0.12 1.40 0.20 1.53 0.29 1.95 0.34 1.07 0.30
(08)
Dichromate/EGF 0.48 0.04 0.63 0.08 1.40 0.13 1.80 0.14 2.30 0.18 1.0 0.14
(18)
Mean serum creatinine (mg %) at various intervals following dichromate injection. hr-EGF was given four hours following dichromate at a dose
of 7 g/l00g rat.
Table 3. Effect ofT3 and T3/EGF on dichromate-induced acute renal failure
0 hr 24 hr 48 hr 72 hr 96 hr 144 hr
Dichromate 0.44 0.06 0.54 0.07 1.77 0.34 2.63 0.76 1.41 0.19 0.38 0.09
(11)
DichromatelT3 0.43 0.03 0.54 0.05 0.98a 0.14 0.9la 0.17 0.71a 0.08 0.43 0.08
(20)
Dichromate/T3/EGF 0.33 0.04 0.34 0.05 0.83a 0.12 0.70a 0.12 0.76a 0.13 0.61 0.08
(20)
Mean serum creatinine (mg %) at various intervals following dichromate injection. T3 was given 1 hour following dichromate at a dose of 10
g/l00 g rat. hr-EGF was given 4 hours following dichromate at a dose of 7 g/100 g rat.
a Statistically different from dichromate alone P < 0.05
Table 4. Effect of dichromate, T3 and EGF on renal EGF levels
24hr 48hr 72hr
Dichromate 4.7 0.3 33.5 6.4 23.1 10
Dichromate/T3 97 0.8 63.2a 20 44.la 8.7
Dichromate/EGF 5.5 1.2 38.5 6.7 21.6 2.7
Whole kidney homogenate ir-EGF (expressed as ng/g wet wt) was
measured at varying intervals following dichromate. T3 was given I
hour following dichromate at a dose of 10 g/l00 g rat. hr-EGF was
given 4 hours following dichromate at 7 g/100 g rat. N = 6 to 8. Data
are means SEM.
a Statistically different from dichromate alone, P < 0.05
EGF, soluble plus associated membrane, actually decreases in
ARF. This decrease in total EGF is consistent with the decrease
in synthesis of the membrane precursor (suggested by the
previously noted decrease in message), and, perhaps, also with
EGF binding its receptor and being internalized and degraded.
We have recently described the same phenomenon in the
setting of ischemic ATN [6, 17] where we have shown that the
immunoreactive EGF binds to receptors and is capable of
stimulating thymidine uptake (that is, it is biologically active).
In the setting of ischemic injury tissue EGF levels rose earlier
(at 24 hours), which is consistent with the more rapid develop-
ment of injury in that model. In that model, both the degree of
tissue injury, as measured by histology, and serum creatinine
levels parallel the rise in soluble renal EGF. The peak in soluble
EGF levels (24 hr) preceded the peak in cellular proliferation
(48 hr) by 24 hours [17]. These data suggest the existence of a
self repair mechanism whereby injured cells release a mitogenic
hormone, EGF, to facilitate recovery. They don't rule out the
scenario outlined above, however. While peak levels of tissue
EGF in the absence of treatment calculate to a concentration of
approximately 10 M (orders of magnitude above the Kd of any
known EGF receptor) it is unclear where the immunoreactive
material is located. EGF is primarily produced in loop of Henle
and distal nephron [18], and much of the injury seen with
dichromate is in proximal nephron segments. While a redistri-
bution of EGF to involve the proximal nephron has been
described in several models of renal injury [19, 20], it remains
conceivable that EGF concentrations in the region of critical
receptors is far lower than Kd values, and that augmentation of
these levels with therapy is necessary to observe the full EGF
effect. Our study provides no direct data on the question of
localization and receptor binding of the intrarenal EGF, but it
does provide inferential evidence that the intrarenal EGF is
related to recovery.
A strong linkage among thyroid hormone, endogenous kidney
EGF, and functional improvement was demonstrated in the
present studies. T3 (employed here rather than T4 which had
previously been shown to be effective in dichromate induced
ARF [10]) caused an approximate doubling of renal EGF at
every time point tested. This correlated with virtually complete
functional protection. The correlation of rise of EGF levels with
injury and fall with recovery suggests a functional role. The
observed protection by T3 from dichromate induced ARF,
along with the increased levels of soluble EGF are consistent
with a direct T3-EGF mechanism. We can only speculate as to
the mechanism of the T3-EGF relationship. The doubling of
EGF levels in ARF caused by T3 may release EGF at a more
effective time or location than that released as a function of
renal injury. These observed results are consistent with our
proposed mechanism, but do not rule out alternative explana-
tions. The mechanism by which T3 increases soluble immuno-
reactive EGF in the setting of renal injury is not directly
addressed by these studies and remains speculative. T3 could
induce either new synthesis of precursors or further stimulate
release from precursors by activation of protease activity.
Functional data acquired where exogenous EGF was given
alone or in concert with T3 were more problematic to interpret.
The fact that EGF rises concomitant with injury in both
dichromate and ischemic [6] ARF does not necessarily preclude
an effect of exogenous EGF. Given as a bolus early following
injury, exogenous EGF could act to attenuate injury or hasten
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recovery prior to the rise in endogenous EGF. However, we
were unable to demonstrate functional protection when EGF
was given four hours after dichromate. Likewise, there was no
evidence of synergism when T3 and EGF were given together.
These data conflict with previous studies where exogenous
EGF has been shown to provide beneficial effects in several
ARF models [2, 3], including at least one heavy metal paradigm
[1]. EGF was administered in the present studies via the same
route in the same dosages and over the same time periods as
previously. Tissue levels of the hrEGF infused were not mea-
sured to document delivery to critical sites (the RIA utilized
measured only endogenous EGF) and it is possible that delivery
dynamics can differ from model to model. Varying responses in
different models of ARF could also relate to differing patterns of
injury [211.
Review of previous studies demonstrates that an important
difference between the present studies and those which dem-
onstrated clear evidence of endogenous EGF protection is
marked differences in the magnitude of ARF induced. Here,
maximal serum creatinines at peak injury were in the range of
2.5 mg %. In the studies of ischemic ARF by Norman et al [3],
maximum control creatinine was near 5 mg %, and following
EGF was 4 mg %. Renal injury induced by HgCI2 in the study
of Coimbra, Cieslinski and Humes [1] was even more severe
with creatinines rising to 10 mg % in the untreated group and
near 6.0 mg % following EGF. Large changes in creatinine
concentration at the lower limits of GFR result from relatively
small changes in clearance. It seems possible that the degree of
functional improvement afforded by exogenous EGF in previ-
ous studies might well have occurred in the present experiments
but were not detectable as a consequence of the less severe
ARF seen here. McKanna and colleagues [22] failed to detect
an effect of exogenous EGF when given in the setting of
ischemic ARF. They also speculated that the induction of less
severe injury in their model compared to that of Humes et al [2]
might explain the disparate findings. Alternatively, it appears
possible that severe injury might compromise intrinsic mecha-
nisms to generate endogenous EGF. In such a situation the
effect of exogenous EGF would be magnified. Since renal levels
of EGF have not been measured in the setting of profound
injury this hypothesis is merely conjectural. EGF may also have
differing effects depending upon degree of injury. In vitro, EGF
has been noted to have variable effects on cellular proliferation
depending on plating density of cultured cells [23]. What is clear
from these results is that, when compared in a single model of
relatively mild ARF, exogenous EGF is not nearly as eftlcious
as T3 in the doses and over the time course studied.
The present study provides strong support for the existence
of a repair mechanism within the kidney that supplies its own
trophic hormone, EGF, to aid in the recovery of renal function
so common to most models of acute renal failure. Additionally,
a strong association between thyroid hormone and increased
tissue EGF is established. Whether the mechanism whereby
thyroid hormone blunts the degree of injury or accelerates
recovery is simply through increasing EGF remains unclear.
More compelling evidence will require experiments where
activation of the endogenous EGF pathway is inhibited. Such
studies employing protease inhibitors to interfere with EGF
release, and antibodies to EGF and inhibitors of EGF depen-
dent modifications to thwart EGF function are currently being
pursued.
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